LoginSignup
Amneal logo

Amneal

Stock
Stock
Ticker: AMRX
AMRX

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Amneal is $5.43B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for Amneal is 35.50. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
Amneal's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.479. EPS indicates the company's profitability on a per-share basis.
Currently, 7 analysts cover Amneal's stock, with a consensus target price of $21.33. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Amneal reported a revenue of $3.12B.
Amneal's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $671.24M. EBITDA measures the company's overall financial performance.
Amneal has a free cash flow of $81.12M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Amneal employs approximately 8,500 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
The free float of Amneal is 143.65M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$5.43B
EPS (TTM) 
$0.479
Free Float 
143.65M
P/E ratio (TTM) 
35.50
Revenue (TTM) 
$3.12B
EBITDA (TTM) 
$671.24M
Free Cashflow (TTM) 
$81.12M

Pricing

1D span
$16.83$17.40
52W span
$9.50$19.26

Analyst Ratings

The price target is $21.33 and the stock is covered by 7 analysts.

Buy

7

Hold

0

Sell

0

Information

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Employees
8,500
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

Primary Ticker
AMRX

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin